Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FQQB2
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $34,949
Award facts
- Contract value 100% obligated
- $34,948.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $34,948.80 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 mL autoinjector units. The delivery order, issued on January 12, 2026, with an ultimate completion date of February 3, 2026, carries no set-aside designation, indicating the contractor won the award through unrestricted federal competition. DMS Pharmaceutical Group will perform the work at its headquarters location in Park Ridge, Illinois, and no subcontractors have been identified in the award documentation.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to establish multiple regional prime vendor contractors. The underlying IDC, valued at $499,999,999 through December 31, 2036, authorizes DLA to issue firm fixed-price delivery orders for comprehensive pharmaceutical products including branded and generic medications, biologics, and medical consumables to support Department of Defense military healthcare facilities worldwide. DMS Pharmaceutical Group's established performance on numerous delivery orders demonstrates its capability to serve as a critical pharmaceutical supplier for federal military medical operations.
Quick answers
Who was awarded contract SPE2DR26FQQB2?
SPE2DR26FQQB2 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 12, 2026.
How much is contract SPE2DR26FQQB2 worth?
The government has obligated $34,949 on SPE2DR26FQQB2.
Is contract SPE2DR26FQQB2 an order under another contract?
Yes. SPE2DR26FQQB2 is a delivery order under SPE2DR25D9331, an indefinite delivery contract.
Was contract SPE2DR26FQQB2 competed?
The extent of competition for SPE2DR26FQQB2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award